Literature DB >> 30546679

A case of fulminant myocarditis treated with very long-term support by cardiopulmonary support system.

Takahiro Mito1, Masao Takemoto1, Yuki Kawano1, Atsushi Tanaka1, Atsutoshi Matsuo1, Satoru Hida1, Hiroyuki Saisyo1, Kouichiro Shimoishi1, Hidetsugu Hori1, Teiji Okazaki1, Kei-Ichiro Tayama1, Kiyonobu Yoshitake1, Kenichi Kosuga1.   

Abstract

Fulminant myocarditis (FM) sometimes causes severe left ventricular dysfunction and lethal arrhythmias leading to cardiogenic shock and critical conditions. Thus, mechanical circulation support with intra-aortic balloon pumping and/or a cardiopulmonary support system (CPS) is sometimes needed to save lives. The special recommended therapies for FM for that classified as class I (evidence level C) in the guidelines of the Japanese Circulation Society are intra-aortic balloon pumping, CPS, percutaneous cardiac pacing, and a left ventricular assist device (LVAD), and they are well established in evidence-based medicine. We experienced a case of FM that we were able to save by long-term stable CPS support. Because, unfortunately, the LVAD was not commercially available in Japan at that time, intensive treatments including CPS were continued in our hospital. Finally, a good course of the illness was achieved without any adverse complications. Thus, these intensive treatments in the present case may be one of the optional effective strategies for FM, especially in hospitals and/or countries where the LVAD is not (commercially) available, and when an LVAD may not be suitable because of complications associated with infectious disease. <Learning objective: Intensive treatment including cardiopulmonary support system as in this case may be one of the optional effective strategies for fulminant myocarditis, especially in hospitals and/or countries where left ventricular assist devices (LVAD) are not (commercially) available, and when an LVAD may not be suitable because of complications associated with infectious disease.>.

Entities:  

Keywords:  Cardiopulmonary support system; Congestive heart failure; Fulminant myocarditis; Long-term

Year:  2016        PMID: 30546679      PMCID: PMC6283725          DOI: 10.1016/j.jccase.2016.07.002

Source DB:  PubMed          Journal:  J Cardiol Cases        ISSN: 1878-5409


  13 in total

1.  National survey of fulminant myocarditis in Japan: therapeutic guidelines and long-term prognosis of using percutaneous cardiopulmonary support for fulminant myocarditis (special report from a scientific committee).

Authors:  Naoyoshi Aoyama; Tohru Izumi; Katsuhiko Hiramori; Mitsuaki Isobe; Masatoshi Kawana; Michiaki Hiroe; Hitoshi Hishida; Yasushi Kitaura; Tsutomu Imaizumi
Journal:  Circ J       Date:  2002-02       Impact factor: 2.993

2.  Fulminant myocarditis survivor after 56 hours of non-responsive cardiac arrest successfully returned to normal life by cardiac resynchronization therapy: a case report.

Authors:  Koichi Sugamura; Seigo Sugiyama; Hiroaki Kawano; Eiji Horio; Shunichi Ono; Sunao Kojima; Koichi Kaikita; Katsuyuki Sagishima; Tomohiro Sakamoto; Michihiro Yoshimura; Yoshihiro Kinoshita; Hisao Ogawa
Journal:  J Cardiol       Date:  2006-12       Impact factor: 3.159

Review 3.  Fulminant myocarditis.

Authors:  Sachin Gupta; David W Markham; Mark H Drazner; Pradeep Pa Mammen
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2008-09-16

Review 4.  Update on myocarditis.

Authors:  Ingrid Kindermann; Christine Barth; Felix Mahfoud; Christian Ukena; Matthias Lenski; Ali Yilmaz; Karin Klingel; Reinhard Kandolf; Udo Sechtem; Leslie T Cooper; Michael Böhm
Journal:  J Am Coll Cardiol       Date:  2012-02-28       Impact factor: 24.094

5.  Predictive score for survival after percutaneous cardiopulmonary support in cardiovascular disease patients- evaluation of pre-procedural information.

Authors:  Akihiro Shirakabe; Ayaka Nozaki; Noritake Hata; Nobuaki Kobayashi; Takuro Shinada; Kazunori Tomita; Masafumi Tsurumi; Masato Matsushita; Hirotake Okazaki; Yoshiya Yamamoto; Shinya Yokoyama; Kuniya Asai; Kyoichi Mizuno
Journal:  Circ J       Date:  2013-04-25       Impact factor: 2.993

6.  Idiopathic giant-cell myocarditis--natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators.

Authors:  L T Cooper; G J Berry; R Shabetai
Journal:  N Engl J Med       Date:  1997-06-26       Impact factor: 91.245

Review 7.  Mechanical circulatory support for patients with acute-fulminant myocarditis.

Authors:  M A Acker
Journal:  Ann Thorac Surg       Date:  2001-03       Impact factor: 4.330

8.  [Successful management of a man with fulminant myocarditis using percutaneous cardiopulmonary support].

Authors:  Makio Ohkawa; Koichi Nishikawa; Tomonori Takazawa; Hiroshi Hinohara; Fumio Kunimoto; Fumio Goto
Journal:  Masui       Date:  2005-02

9.  Fulminant myocarditis treated with percutaneous cardiopulmonary support system (PCPS).

Authors:  Kiyohiro Oshima; Fumio Kunimoto; Hiroshi Hinohara; Yoshiro Hayashi; Junko Hirato; Yukio Tajima; Hiroyuki Kuwano
Journal:  Ann Thorac Cardiovasc Surg       Date:  2008-04       Impact factor: 1.520

10.  Gamma-globulin treatment of acute myocarditis in the pediatric population.

Authors:  N A Drucker; S D Colan; A B Lewis; A S Beiser; D L Wessel; M Takahashi; A L Baker; A R Perez-Atayde; J W Newburger
Journal:  Circulation       Date:  1994-01       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.